The BIOQUANT OSTEO software enables cutting-edge bone biology research in animal models. It supports both high-throughput automation and precise manual interaction for ASBMR standard bone histomorphometry. Unique tools simplify skeletal phenotyping, arthritis model assessment, help characterize cancer metastasis, aid in forensic anthropology, and quantify implant osseointegration.
BIOQUANT OSTEO 12.1

Recent BIOQUANT OSTEO Citations
-
Inactivation of a Novel FGF23 Regulator, FAM20C, Leads to Hypophosphatemic Rickets in Mice
AuthorsXiaofang Wang, Suzhen Wang, Changcheng Li, Tian Gao, Ying Liu, Afsaneh Rangiani, Yao Sun, Jianjun Hao, Anne George, Yongbo Lu, Jay Groppe, Baozhi Yuan, Jian Q. Feng, Chunlin QinAbstractFamily with sequence similarity 20,-member C (FAM20C) is highly expressed in the mineralized tissues of mammals. Genetic studies showed that the loss-of-function mutations in FAM20C were associated with human lethal osteosclerotic bone dysplasia (Raine Syndrome), implying an inhibitory role of this molecule in bone formation. However, in vitro gain- and loss-of-function studies suggested that FAM20C promotes the differentiation and mineralization of mouse mesenchymal cells and odontoblasts. Recently, we generated Fam20c conditional knockout (cKO) mice in which Fam20c was globally inactivated (by crossbreeding with Sox2 ...
Posted May 29, 2012 11:52 AM by Nathanael Reveal
Browse all BIOQUANT OSTEO citations... |
The BIOQUANT LIFE SCIENCE software enables cutting edge bioscience research in animal models. It supports high-throughput immunofluorescence and immunohistochemistry, stereology, densitometry, and 3D modeling. Primary applications include developmental neuroscience, traumatic brain/spinal cord injury, glaucoma, eye-movement disorders, cardiovascular disease and muscle disorders.
Learn more about BIOQUANT LIFE SCIENCE...
View the Life Science 2012 Media Kit
BIOQUANT LIFE SCIENCE 12.5
Recent BIOQUANT LIFE SCIENCE Citations
-
Gene Therapy for Muscular Dystrophy: Lessons Learned and Path Forward
AuthorsJerry R. Mendell, Louise Rodino-Klapac, Zarife Sahenk, Vinod Malik, Brian K. Kaspar, Christopher M. Walker, K. Reed ClarkAbstractOur Translational Gene Therapy Center has used small molecules for exon skipping and mutation suppression and gene transfer to replace or provide surrogate genes as tools for molecular-based approaches for the treatment of muscular dystrophies. Exon skipping is targeted at the pre-mRNA level allowing one or more exons to be omitted to restore the reading frame. In Duchenne Muscular Dystrophy (DMD), clinical trials have been performed with two different oligomers, a 2′O-methyl-ribo-oligonucleoside-phosphorothioate (2′OMe) and a phosphorodiamidate morpholino (PMO). Both have demonstrated early evidence of efficacy. A second molecular approach involves suppression ...
Posted May 22, 2012 9:36 AM by Nathanael Reveal
|
You must be logged in to add gadgets that are only visible to you